^
    Back
    Association details:
    Biomarker:EML4-ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer Genomics Proteomics
    Title:

    Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma

    Published date:
    07/04/2023
    Excerpt:
    ...patients with EML4-ALK fusion treated by alectinib was significantly favorable compared to patients without any targetable variant treated by chemotherapy (p=0.0172, p=0.0096, respectively).
    DOI:
    10.21873/cgp.20392
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence

    Published date:
    05/26/2022
    Excerpt:
    Patients with ALK-positive advanced NSCLC, who received crizotinib or alectinib treatment in first line, were retrospectively reviewed....Clinical outcomes have been comprehensively analyzed between TKIs, ALK fusions, EML4-ALK variants, and next-generation TKIs after crizotinib failure....Patients in EML4 group had a better prognosis than those in non-EML4 group after alectinib administration (HR 0.13, 95% CI: 0.03–0.60, p = 0.009)....Our results revealed alectinib had better PFS and higher intracranial efficacy compared to crizotinib in ALK-positive NSCLC, and might improve PFS by comparison with ceritinib and brigatinib after crizotinib failure.
    DOI:
    https://doi.org/10.1002/cam4.4834
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Int J Cancer
    Title:

    Special issue “The advance of solid tumor research in China”: Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China

    Published date:
    05/17/2022
    Excerpt:
    Patients with advanced non-small-cell lung cancer (NSCLC) and EML4–ALK fusion were enrolled...The primary endpoints were objective response rate (ORR) and progression-free survival (PFS) to alectinib.…The 1- and 2-year PFS rates were 77.4% and 68.3%, respectively. ORR and disease control rate (DCR) were 53.5% and 91.3%, respectively.
    DOI:
    https://doi.org/10.1002/ijc.34123